WallStreetZenWallStreetZen

NYSE: HLN
Haleon PLC Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

HLN past earnings growth

How has HLN's earnings growth performed historically?
Company
4.33%
Industry
13.39%
Market
61.16%
HLN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
HLN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
HLN's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

HLN past revenue growth

How has HLN's revenue growth performed historically?
Company
9.36%
Industry
10.23%
Market
16.96%
HLN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
HLN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
HLN's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

HLN earnings and revenue history

Current Revenue
$14.3B
Current Earnings
$1.3B
Current Profit Margin
9.3%

HLN Return on Equity

Current Company
6.4%
Current Industry
15.4%
Current Market
188%
HLN's Return on Equity (6.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when HLN announces earnings.

HLN Return on Assets

Current Company
3%
Current Industry
3.4%
HLN is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

HLN Return on Capital Employed

Current Company
6.57%
Current Industry
5.1%
HLN has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

HLN vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
HLN$14.31B$2.70B$1.33B+6.41%-88.62%
TAK$28.38B$7.34B$1.21B+12.67%-8.81%
TEVA$15.85B$1.64B-$559.00M-2.81%N/A
NBIX$1.89B$358.00M$249.70M+33.13%+61.92%
VTRS$15.43B$3.52B$54.70M+6.17%-40.84%
View Top Pharmaceutical Stocks

HLN earnings dates

Next earnings date
May 1, 2024

Haleon Earnings & Revenue FAQ

What were HLN's earnings last quarter?

On Invalid Date, Haleon (NYSE: HLN) reported Q4 2023 earnings per share (EPS) of N/A, up N/A year over year. Total Haleon earnings for the quarter were N/A. In the same quarter last year, Haleon's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Haleon stock.

What was HLN's earnings growth in the past year?

As of Q2 2024, Haleon's earnings has grown 4.33% year over year. This is 9.05 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 13.39%. Haleon's earnings in the past year totalled $1.33 billion.

What is HLN's earnings date?

Haleon's earnings date is Invalid Date. Add HLN to your watchlist to be reminded of HLN's next earnings announcement.

What was HLN's revenue last quarter?

On Invalid Date, Haleon (NYSE: HLN) reported Q4 2023 revenue of N/A up N/A year over year. In the same quarter last year, Haleon's revenue was N/A.

What was HLN's revenue growth in the past year?

As of Q2 2024, Haleon's revenue has grown 9.36% year over year. This is 0.87 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.23%. Haleon's revenue in the past year totalled $14.31 billion.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.